TY - JOUR
T1 - Polycystic ovary syndrome and cardiometabolic risk
T2 - Opportunities for cardiovascular disease prevention
AU - Osibogun, Olatokunbo
AU - Ogunmoroti, Oluseye
AU - Michos, Erin D.
N1 - Publisher Copyright:
© 2019 The Author(s)
PY - 2020/10
Y1 - 2020/10
N2 - Although polycystic ovary syndrome (PCOS) is one of the most common endocrine disorders affecting women, its etiology is not entirely understood. Clinical symptoms of PCOS include acne, amenorrhea or oligomenorrhea, hirsutism, infertility, and mood disorders, which tend to be the primary focus of clinical management. However, the impact of PCOS on future cardiovascular disease (CVD) risk should not be overlooked, and opportunities to implement CVD prevention strategies in these women should be given high priority. The pathogenesis of PCOS commonly involves insulin resistance which leads to several cardiometabolic abnormalities (e.g., dyslipidemia, hypertension, glucose intolerance, diabetes, and metabolic syndrome), thereby putting women at an increased risk for CVD. Prior studies have found that subclinical CVD markers such as coronary artery calcium scores, C-reactive protein, carotid intima-media thickness, and endothelial dysfunction are more likely to be increased in women with PCOS. While the associations between PCOS and cardiometabolic abnormalities have been well established, whether PCOS is associated with subclinical and clinical CVD, independently of these CVD risk factors, is not entirely clear. Lifestyle interventions and weight management may mitigate some of these future CVD risks and should be encouraged. This review summarizes the literature on PCOS and CVD risk factors and provides recommendations that would aid clinicians in the management of these risk factors.
AB - Although polycystic ovary syndrome (PCOS) is one of the most common endocrine disorders affecting women, its etiology is not entirely understood. Clinical symptoms of PCOS include acne, amenorrhea or oligomenorrhea, hirsutism, infertility, and mood disorders, which tend to be the primary focus of clinical management. However, the impact of PCOS on future cardiovascular disease (CVD) risk should not be overlooked, and opportunities to implement CVD prevention strategies in these women should be given high priority. The pathogenesis of PCOS commonly involves insulin resistance which leads to several cardiometabolic abnormalities (e.g., dyslipidemia, hypertension, glucose intolerance, diabetes, and metabolic syndrome), thereby putting women at an increased risk for CVD. Prior studies have found that subclinical CVD markers such as coronary artery calcium scores, C-reactive protein, carotid intima-media thickness, and endothelial dysfunction are more likely to be increased in women with PCOS. While the associations between PCOS and cardiometabolic abnormalities have been well established, whether PCOS is associated with subclinical and clinical CVD, independently of these CVD risk factors, is not entirely clear. Lifestyle interventions and weight management may mitigate some of these future CVD risks and should be encouraged. This review summarizes the literature on PCOS and CVD risk factors and provides recommendations that would aid clinicians in the management of these risk factors.
KW - Cardiovascular risk
KW - Insulin resistance
KW - Polycystic ovarian syndrome
KW - Prevention
KW - Women
UR - http://www.scopus.com/inward/record.url?scp=85071968166&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85071968166&partnerID=8YFLogxK
U2 - 10.1016/j.tcm.2019.08.010
DO - 10.1016/j.tcm.2019.08.010
M3 - Review article
C2 - 31519403
AN - SCOPUS:85071968166
SN - 1050-1738
VL - 30
SP - 399
EP - 404
JO - Trends in Cardiovascular Medicine
JF - Trends in Cardiovascular Medicine
IS - 7
ER -